G1 Ther­a­peu­tics aban­dons PhI­II col­orec­tal can­cer tri­al af­ter dis­ap­point­ing over­all re­sponse rates

On­col­o­gy-fo­cused G1 Ther­a­peu­tics aban­doned a Phase III tri­al test­ing tri­laci­clib in com­bi­na­tion with oth­er drugs in pa­tients with metasta­t­ic col­orec­tal can­cer af­ter dis­ap­point­ing re­sults.

In the PRE­SERVE 1 study, pa­tients re­ceiv­ing place­bo be­fore a chemother­a­py reg­i­men called FOL­FOXIRI as well as Avastin (be­va­cizum­ab) saw bet­ter ear­ly an­ti-tu­mor ef­fi­ca­cy than those who got tri­laci­clib plus FOL­FOXIRI and Avastin, in­clud­ing re­sponse to the drugs and pre­lim­i­nary mea­sures of sur­vival. The com­pa­ny an­nounced the tri­al ter­mi­na­tion af­ter it de­ter­mined tri­laci­clib would be un­like­ly to hit pro­gres­sion-free sur­vival and over­all sur­vival end­points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.